-
Over-the-counter contraceptive products that contain the spermicide nonoxynol-9 (N-9) now will carry a warning label to alert consumers that such products do not protect against sexually transmitted diseases (STDs) and HIV/AIDS, following a final ruling by the Food and Drug Administration (FDA).
-
Tick off the contraceptive options now available at your clinic. If you are a provider at a university health center, chances are your list may be shorter than it was in 2007.
-
With results just published for a Phase I clinical trial and data for a Phase I/II trial in analysis, developers of what is being dubbed the Invisible Condom are looking toward initiation of a Phase III randomized controlled trial to test the safety and efficacy of the potential microbicide.
-
-
Results from a new Guttmacher Institute analysis indicate that current state-mandated abortion counseling requirements often violate core principles of informed consent.
-
What percentage of women choose sterilization as their contraceptive option in your practice? Chances are it is a significant proportion. According to the National Center for Health Statistics, 17% of all women ages 15-44 rely on female sterilization for birth control.
-
The number, type, and severity of comorbidities are important determinants of diabetes self-care.
-
Patients with mild-to-moderate obstructive sleep apnea (OSA) who were treated with Continuous Positive Airway Pressure (CPAP) experienced an absolute risk reduction in cardiovascular risk compared with those who were not treated.
-
Absent or low testosterone levels in men appear to have a pathogenic role in the development of cardiovascular disease resulting in increased cardiovascular and all-cause mortality and are not simply "markers" for illness or wellness.
-
The FDA has approved, by priority review, the first drug to help manage patients with phenylketonuria (PKU).
